tbuckley/cabot-search huggingface dataset:
A phase III randomized study of gilteritinib versus salvage chemotherapy in FLT3 mutation-positive subjects with relapsed or refractory acute myeloid leukemia
Authors: J. Wang, J. Li, A. Tantiworawit, S. Izuka, S. Yamada, J. Hill, E. Shima Rich, E. Bahceci
Journal: Annals of Oncology (2018)
Role of Low-Dose Computerized Tomography in Lung Cancer Screening among Never-Smokers
Authors: Hye-Rin Kang, Jun Yeun Cho, Sang Hoon Lee, Yeon Joo Lee, Jong Sun Park, Young-Jae Cho, Ho Il Yoon, Kyung Won Lee, Jae Ho Lee, Choon-Taek Lee
Journal: Journal of Thoracic Oncology (2018)
Treatment with allogeneic mesenchymal stromal cells for moderate to severe acute respiratory distress syndrome (START study): a randomised phase 2a safety trial
Authors: Michael A Matthay, Carolyn S Calfee, Hanjing Zhuo, B Taylor Thompson, Jennifer G Wilson, Joseph E Levitt, Angela J Rogers, Jeffrey E Gotts, Jeanine P Wiener-Kronish, Ednan K Bajwa, Michael P Donahoe, Bryan J McVerry, Luis A Ortiz, Matthew Exline, John W Christman, Jason Abbott, Kevin L Delucchi, Lizette Caballero, Melanie McMillan, David H McKenna, Kathleen D Liu
Journal: The Lancet Respiratory Medicine (2018)
The T-box transcription factor Brachyury controls tumor cell migration and invasion
Authors: Romaine Fernando, Paola Trono, Mary Litzinger, Jeffrey Schlom, Claudia Palena
Journal: Cancer Research (2008)

4553   Elevated expression of the T-box transcription factor Brachyury has been demonstrated in various human tumors of epithelial origin and in human cell lines derived from lung, colon, and prostate carcinomas (Clin Cancer Res. 2007;13(8):2471-8). Brachyury9s high expression in tumor cells contrasts with its lack of expression in most human normal adult tissues. The function of Brachyury as a relevant gene for the development of mesoderm during gastrulation is well established; however, no reports exist so far indicating its function in the context of a tumor cell. Formation of mesoderm during embryogenesis is a manifestation of epithelial plasticity where epithelial cells change into mesenchymal cells by triggering an epithelial-to-mesenchymal transition (EMT). Recently, EMT has been recognized as a central process in the progression of primary tumors into metastasis, which involves the acquisition of motility and invasiveness by the tumor cells. Several transcription factors involved in the control of mesoderm such as Twist, Snail and Slug have been identified as controllers or triggers of EMT. Here, we sought to investigate the role of Brachyury in the EMT process during tumor progression. Two experimental approaches were taken in which (1) the expression of Brachyury has been silenced in Brachyury-positive human lung carcinoma cells, or (2) Brachyury has been over-expressed in various human tumor cell lines that are Brachyury-negative. Our results demonstrated that stable silencing of Brachyury expression in carcinoma cells results in down-regulation of mesenchymal markers and up-regulation of epithelial markers with concomitant loss of cell migration and invasion functions. In contrast, the over-expression of Brachyury in several tumor cell lines resulted in up-regulation of mesenchymal markers and down-regulation of epithelial markers, and increased both the migration and invasiveness of the tumor cells. Therefore, our results demonstrate that the transcription factor Brachyury plays a role in the EMT process during tumor progression, conferring on the tumor cells a mesenchymal phenotype as well as migratory and invasive abilities. The high expression of Brachyury in tumor cells and its potential role in the metastatic conversion of tumors make Brachyury an attractive target candidate for anti-tumor mediated therapies.
Abstract 13193: Impact of “Off-Peak” Versus “Peak” Hour Coronary Interventions for ST-Elevation Myocardial Infarction on Adverse Outcomes
Authors: Jae S Lee, Gabriel Redel-Traub, Michael Kim, Perwaiz Meraj, Christina Brennan, Venkatesan Vidi
Journal: Circulation (2015)

Background: In addition to patient-dependent factors, whether the time of arrival of the patient to the hospital with ST-elevation myocardial infarction (STEMI) might play a role in subsequent adverse outcomes following primary percutaneous coronary interventions (PCI) is not well studied. Method: 856 PCI procedures for patients presenting with STEMI from two large hospitals in the health system were analyzed. Peak hours were defined as procedures performed between 7 AM and 7 PM on weekdays. Off-peak hours were defined as procedures performed between 7 PM and 7 PM on weekdays and weekends. Unadjusted and propensity score-adjusted analyses were performed to analyze the following inpatient outcomes: composite of death/MI/stroke, composite of bleeding events, composite of death/MI/stroke/bleeding endpoints, and long-term mortality. Results: Of 856 PCIs, 407 (47.5%) were performed during the peak hours. In both unadjusted and propensity score-adjusted analyses, no significant differences in adverse outcomes and long-term mortality were observed in patients who had PCIs during off-peak and peak hours (see Table). In addition, a separate analysis performed on patients who underwent primary PCIs between 7 AM-7 PM (“Morning”) versus 7 PM-7 AM (“Evening”) on all days showed no difference in the inpatient adverse outcomes and long-term mortality (Adjusted long term mortality: HR 0.79 (95% CI 0.40-1.56), p=0.49). Conclusion: Primary PCIs performed on patients presenting with STEMI during off-peak versus peak hours results in similar inpatient adverse outcomes and long-term mortality.
Optimal Insulin Correction Factor in Post–High-Intensity Exercise Hyperglycemia in Adults With Type 1 Diabetes: The FIT Study
Authors: Ronnie Aronson, Ruth E. Brown, Aihua Li, Michael C. Riddell
Journal: Diabetes Care (2018)

Postexercise hyperglycemia, following high-intensity interval training (HIIT) in patients with type 1 diabetes (T1D), is largely underrecognized by the clinical community and generally undertreated. The aim of this study was to compare four multipliers of an individual's insulin correction factor (ICF) to treat post-HIIT hyperglycemia.The FIT study had a randomized, crossover design in physically active subjects with T1D (mean ± SD age 34.9 ± 10.1 years, BMI 25.5 ± 2.5 kg/m2, and HbA1c 7.2 ± 0.9%) using multiple daily injections. Following an 8-week optimization period, with 300 units/mL insulin glargine used as the basal insulin, subjects performed four weekly sessions of 25 min of HIIT. If hyperglycemia (>8.0 mmol/L) resulted, subjects received a bolus insulin correction 15 min post-HIIT, based on their own ICF, adjusted by one of four multipliers: 0, 50, 100, or 150%.Seventeen subjects completed 71 exercise trials, of which 64 (90%) resulted in hyperglycemia. At 40 min postexercise, plasma glucose (PG) increased from mean ± SD 8.8 ± 1.0 mmol/L at baseline to 12.7 ± 2.4 mmol/L (increase of 3.8 ± 1.5 mmol/L). After correction, adjusted mean ± SE PG was significantly reduced for the 50% (-2.3 ± 0.8 mmol/L, P < 0.01), 100% (-4.7 ± 0.8 mmol/L, P < 0.001), and 150% (-5.3 ± 0.8 mmol/L, P < 0.001) arms but had increased further in the 0% correction arm. Both the 100 and 150% corrections were more effective than the 50% correction (P < 0.01 and P < 0.001, respectively) but were not different from each other. Hypoglycemia was rare.In post-HIIT hyperglycemia, correction based on a patient's usual ICF is safe and effective. Optimal PG reduction, with minimal hypoglycemia, occurred in the 100 and 150% correction arms.
Association of immune-related pneumonitis with the phenotypic appearance of concurrent ILD in patients treated with anti-PD-1 antibody
Authors: R. Shibaki, S. Murakami, Y. Matsumoto, Y. Goto, S. Kanda, H. Horinouchi, Y. Fujiwara, N. Yamamoto, Y. Ohe
Journal: Annals of Oncology (2018)
Comparison Of Sequential Vs Alternating Administration Of Bortezomib, Melphalan and Prednisone (VMP) and Lenalidomide Plus Dexamethasone (Rd) In Elderly Patients With Newly Diagnosed Multiple Myeloma (MM) Patients: GEM2010MAS65 Trial
Authors: Maria-Victoria Mateos, Joaquín Martínez-López, Miguel T. Hernandez, Rafael Martinez, Laura Rosiñol, Enrique M. Ocio, Maria Asunción Echeveste, Jaime Pérez de Oteyza, Albert Oriol, Bargay Joan, Gironella Mercedes, Jesús Martín, Carmen Cabrera, Norma Gutierrez, Martín María Luisa, Javier de la Rubia, Joan Blade, Juan José Lahuerta, Jesús F San Miguel
Journal: Blood (2013)
Multifunctional Coatings and Nanotopographies: Toward Cell Instructive and Antibacterial Implants
Authors: Carlos Mas‐Moruno, Bo Su, Matthew J. Dalby
Journal: Advanced Healthcare Materials (2018)

Abstract In biomaterials science, it is nowadays well accepted that improving the biointegration of dental and orthopedic implants with surrounding tissues is a major goal. However, implant surfaces that support osteointegration may also favor colonization of bacterial cells. Infection of biomaterials and subsequent biofilm formation can have devastating effects and reduce patient quality of life, representing an emerging concern in healthcare. Conversely, efforts toward inhibiting bacterial colonization may impair biomaterial–tissue integration. Therefore, to improve the long‐term success of medical implants, biomaterial surfaces should ideally discourage the attachment of bacteria without affecting eukaryotic cell functions. However, most current strategies seldom investigate a combined goal. This work reviews recent strategies of surface modification to simultaneously address implant biointegration while mitigating bacterial infections. To this end, two emerging solutions are considered, multifunctional chemical coatings and nanotopographical features.
Screening for cardiac contractile dysfunction using an artificial intelligence–enabled electrocardiogram
Authors: Zachi I. Attia, Suraj Kapa, Francisco Lopez-Jimenez, Paul M. McKie, Dorothy J. Ladewig, Gaurav Satam, Patricia A. Pellikka, Maurice Enriquez-Sarano, Peter A. Noseworthy, Thomas M. Munger, Samuel J. Asirvatham, Christopher G. Scott, Rickey E. Carter, Paul A. Friedman
Journal: Nature Medicine (2018)
Association Between Cigarette Smoking and Alcohol Consumption and Sessile Serrated Polyps in Subjects 30 to 49 Years Old
Authors: Ji Young Lee, Hye-Sook Chang, Tae Hyup Kim, Eun Ju Chung, Hye Won Park, Jong-Soo Lee, Sun Mi Lee, Dong-Hoon Yang, Jaewon Choe, Jeong-Sik Byeon
Journal: Clinical Gastroenterology and Hepatology (2018)
AB0811 Increased levels of serum wisteria floribunda agglutinin-positive mac-2 binding protein in systemic sclerosis
Authors: Y. Yokoyama, T. Yoshikawa, T. Furukawa, T. Hashimoto, M. Morimoto, N. Azuma, M. Kitano, T. Iwasaki, K. Matsui, H. Sano
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Mac-2 binding protein is a cell-adhesive glycoprotein of the extracellular matrix secreted as a ligand of galectin-3 (Mac-2). Recently, a Wisteria floribunda agglutinin positive-M2BP (M2BP) assay developed using a lectin-antibody sandwich immunoassay has shown promise as a new fibrotic marker in liver fibrosis and interstitial lung disease (ILD) to detect unique fibrosis-related glycoalteration. Systemic sclerosis (SSc) is an intractable connective tissue disease that causes skin and organ fibrosis. Progressive fibrosis is now recognised to be one of the major causes of morbidity and mortality in SSc. <h3>Objectives</h3> The aim of this study is to evaluate the utility of serum M2BP levels in patients with SSc. <h3>Methods</h3> We retrospectively measured serum M2BP levels in 76 patients with SSc and 16 healthy controls (HC). We excluded patients of viral hepatitis and cirrhosis. Serum levels of M2BP were measured using HISCL<sup>®</sup> M2BP glycosylation isomer Assay Kit. IHC was performed on 5 samples of normal skin, 7 stored samples of SSc skin and 2 samples of SSc-ILD lung tissue. We examined the relationship between serum M2BP levels and clinical parameters in patients with SSc. <h3>Results</h3> The mean age was 62.7 years in SSc patients and 54.6 years in HC. There were 57 limited cutaneous SSc patients and 19 diffuse cutaneous SSc patients. The mean duration of SSc patients was 9.8 years. Serum M2BP levels were significantly higher in patients with SSc than in HC (0.853±0.701 cutoff index [COI], 0.325±0.111 COI, respectively; p&lt;0.00001). Receiver operating characteristic (ROC) curve analysis indicated that serum M2BP correctly differentiated between SSc patients and HC with a sensitivity of 81.6% and specificity of 87.5%. In patients with SSc, a significant correlation was not found between serum M2BP levels and age, sex, mRSS, ILD, pulmonary artery hypertension (PAH), SSc-types, dermatoscopy findings. In multivariant analysis, disease duration was a only independent factor for higher serum M2BP levels more than 0.64 COI, serum M2BP median (odds ratio 0.935, 95% CI 0.878–0.996, p=0.0385). We detected the protein level of M2BP in SSc patient`s fibroblast of skin and SSc Patient`s proliferating type II alveolar cells adjacent to fibrotic lesions of lung tissue. <h3>Conclusions</h3> In this study, for the first we demonstrated that M2BP is expressed in skin and lung tissue in SSc patients in IHC and more over the serum M2BP level tends to be higher in patients with short disease duration. It is reveal that M2BP play an important role of fibrosis in early stage of SSc. The serum level of M2BP may be a novel biomarker of SSc. <h3>Disclosure of Interest</h3> None declared
Multivariable Modeling of Disease and Treatment Characteristics of Adults with B-ALL in MRD-Negative CR after CD19 CAR-T Cells Identifies Factors Impacting Disease-Free Survival
Authors: Kevin A. Hay, Jordan Gauthier, Alexandre V. Hirayama, Jenna M. Voutsinas, Qian V. Wu, Daniel Li, Ted Gooley, Alyssa Sheih, Janaki Purushe, Sindhu Cherian, Xueyan Chen, Barbara S. Pender, Reed M. Hawkins, Aesha Vakil, Rachel N. Steinmetz, Tinh-Doan Phi, Aude G. Chapuis, Brian G. Till, Hans-Peter Kiem, Jorge Ramos, Mazyar Shadman, Ryan D. Cassaday, Utkarsh H. Acharya, Stanley R. Riddell, David G. Maloney, Cameron J. Turtle
Journal: Blood (2018)
Alteration of muscle mass after chemotherapy in patients with newly diagnosed multiple myeloma
Authors: S. Nakamura, H. Miki, Y. Okamoto, K. Sogabe, M. Oura, M. Takahashi, M. Iwasa, T. Harada, S. Fujii, K. Kagawa, M. Abe
Journal: Annals of Oncology (2018)
Synchronous Metastatic Breast Carcinoma and Parathyroid Adenoma on 18F-FDG PET/CT and 99mTc-Sestamibi Imaging
Authors: Harkamal Singh, Daniel J. Wale, Ka Kit Wong, Milton D. Gross, Benjamin L. Viglianti
Journal: Clinical Nuclear Medicine (2018)

In addition to nuclear cardiac and breast imaging, Tc-sestamibi scintigraphy is often used to localize parathyroid adenomas. F- fluorodeoxyglucose (FDG) PET is heavily utilized in oncology, although its use in identifying parathyroid adenomas is limited. We describe a case of a 57-year-old woman who underwent parathyroid scintigraphy and F-FDG PET/CT in the same week due to hyperparathyroidism and an enlarging breast mass, respectively. A right paratracheal mediastinal mass that otherwise would be suspicious for nodal metastases by CT alone was correctly identified to be an ectopic parathyroid adenoma using a combination of the nuclear medicine studies performed.
Abstract 15579: Post-Traumatic Stress Disorder and Heart Failure Among a Nationwide Sample of US Veterans
Authors: Lukasz P Cerbin, Marat Fudim, Srikant Devaraj, Tarek Ajam, Sunil V Rao, Masoor Kamalesh
Journal: Circulation (2017)

Background: Patients with post-traumatic stress disorder (PTSD) are at risk for multiple comorbidities and are more likely to develop incident heart failure (HF). We examined the prevalence and ass...
The DNA Methylation Maintenance Protein UHRF1 Regulates Fetal Globin Expression Independent of HBG Promoter DNA Methylation
Authors: Ruopeng Feng, Phillip A Doerfler, Yu Yao, Xing Tang, Yong-Dong Wang, Chunliang Li, David E. Root, Yong Cheng, Mitchell J. Weiss
Journal: Blood (2018)
Abstract #4626: Role of protein phosphatase 2A in regulation of cell motility
Authors: Lei Liu, Long Chen, Peter Houghton, Shile Huang
Journal: Cancer Research (2009)

Serine/threonine (Ser/Thr) protein phosphatase 2A (PP2A) has been implicated as a component of the mammalian target of rapamycin (mTOR) signaling pathway. Recently we have demonstrated that mTOR regulates cell motility through p70 S6 kinase 1 (S6K1) and eukaryotic initiation factor 4E (eIF4E) binding protein 1 (4E-BP1) pathways. Little is known about the role of PP2A in the mTOR-mediated cell motility. Here we show that rapamycin inhibits the basal or insulin-like growth factor 1 (IGF-1)-induced motility of human Ewing sarcoma (Rh1) and rhabdomyosarcoma (Rh30) cells. Treatment of the cells with rapamycin activates PP2A activity, and concurrently inhibits IGF-1 stimulated phosphorylation of Erk1/2. PD98059 alone did not significantly affect the basal mobility of the cells, but dramatically inhibited IGF-1-induced cell motility. When used in combination with rapamycin, PD98059 did not show a significant additive or synergistic effect on rapamycin inhibition of IGF-1-stimulated cell motility. In contrast, inhibition of PP2A with okadaic acid significantly attenuated the inhibitory effect of rapamycin on IGF-1-stimulated cell motility. Consistently, expression of dominant negative (dn) PP2A (L199P) enhanced phosphorylation of Erk1/2, and conferred to resistance to rapamycin inhibition of cell motility. The results indicate that rapamycin inhibits cell motility in part by activation of PP2A, leading to inhibition of Erk1/2. Our findings suggest that PP2A-Erk1/2 pathway is also very critical for mTOR-mediated cell motility. Supported by NIH R01 CA115414.  Citation Information: In: Proc Am Assoc Cancer Res; 2009 Apr 18-22; Denver, CO. Philadelphia (PA): AACR; 2009. Abstract nr 4626.
CATARACTS: Challenge on automatic tool annotation for cataRACT surgery
Authors: Hassan Al Hajj, Mathieu Lamard, Pierre-Henri Conze, Soumali Roychowdhury, Xiaowei Hu, Gabija Maršalkaitė, Odysseas Zisimopoulos, Muneer Ahmad Dedmari, Fenqiang Zhao, Jonas Prellberg, Manish Sahu, Adrian Galdran, Teresa Araújo, Duc My Vo, Chandan Panda, Navdeep Dahiya, Satoshi Kondo, Zhengbing Bian, Arash Vahdat, Jonas Bialopetravičius, Evangello Flouty, Chenhui Qiu, Sabrina Dill, Anirban Mukhopadhyay, Pedro Costa, Guilherme Aresta, Senthil Ramamurthy, Sang-Woong Lee, Aurélio Campilho, Stefan Zachow, Shunren Xia, Sailesh Conjeti, Danail Stoyanov, Jogundas Armaitis, Pheng-Ann Heng, William G. Macready, Béatrice Cochener, Gwenolé Quellec
Journal: Medical Image Analysis (2018)
Clinicopathological features of ALK protein in 9889 non-small-cell lung cancer specimens and genomic rearrangement identified by capture-based next-generation sequencing: A Chinese retrospective analysis
Authors: R. Zhao, J. Zhang, Y. Han, J. Shao, L. Zhu, C. Xiang, Q. Zhang, H. Teng, G. Qin, L. Zhao, M. Ye, J. Zhao, W. Ding
Journal: Annals of Oncology (2018)
Loss of an IgG plasma cell checkpoint in patients with lupus
Authors: Jolien Suurmond, Yemil Atisha-Fregoso, Emiliano Marasco, Ashley N. Barlev, Naveed Ahmed, Silvia A. Calderon, Mei Yin Wong, Meggan C. Mackay, Cynthia Aranow, Betty Diamond
Journal: Journal of Allergy and Clinical Immunology (2018)
Chronic rhinosinusitis in elderly patients is associated with an exaggerated neutrophilic proinflammatory response to pathogenic bacteria
Authors: Justin C. Morse, Ping Li, Kim A. Ely, Meghan H. Shilts, Todd J. Wannemuehler, Li-Ching Huang, Quanhu Sheng, Naweed I. Chowdhury, Rakesh K. Chandra, Suman R. Das, Justin H. Turner
Journal: Journal of Allergy and Clinical Immunology (2018)
MicroRNA profiling is more stable than messenger RNA against RNA degradation
Authors: Kaho Minoura, Yuko Sawada, Marc Valer, Hui Wang
Journal: Cancer Research (2008)

5029  The RNA integrity is critical in obtaining meaningful gene expression data. Although using intact messenger RNA (mRNA) is key to ensure the reliability of gene expression profiling, there are difficulties in obtaining intact total RNA from clinical specimens. Recent studies show that microRNA (miRNA) expression profiling holds great promise in human disease characterization, potentially as defining markers for tumor classification and biomarkers. Small RNA molecules, such as miRNAs, are expected to be less affected by random RNA degradation, but the impact of RNA degradation on miRNA profiling has not been characterized. Using the Agilent microarray platforms, we examined the effect of RNA degradation using heat treatments by comparing the untreated and the corresponding degraded RNA samples for changes in mRNA and miRNA expression profiles. The impact of degradation treatments on the RNA sample was monitored with the Agilent 2100 Bioanalyzer, a microfluidic capillary electrophoresis system that provides an RNA Integrity Number (RIN), and a separate small RNA assay. Our results showed that the miRNA expression profile is less affected by the degradation treatments than the mRNA profiles. This result shows the potential of miRNA to profile more degraded RNA from clinical specimens.
Single-institute, retrospective study of metastatic uveal melanoma in the immune check point inhibitor era
Authors: S. kazuhiro, K. Sugiyama, K. Nozawa, Y. Funahashi, Y. Kogure, C. Kitagawa, S. Ichihara, R. Nishimura, T. Kubota, H. Saka
Journal: Annals of Oncology (2018)
Pacritinib in Patients with Myelofibrosis—Reply
Authors: John O. Mascarenhas
Journal: JAMA Oncology (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal